Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Patients With Pleural Metastases From Thymic Malignancies
Summary
The researchers are doing this study to find out whether hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) is a safe treatment that causes few or mild side effects in people with pleural metastases from thymic malignancies. The researchers will also look at whether hemithoracic IMPRINT is effective against participants' cancer.
Arms & interventions
- RadiationIntensity-Modulated Pleural Radiation Therapy (IMPRINT)
Radiation therapy will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions, including an optional dose-painting SIB to gross residual disease up to 60 Gy while respecting normal tissue constraints.
Outcome measures
Primary
assess the rate of radiation pneumonitis
as indicated by the rate of grade 3 or higher radiation pneumonitis defined by the NCI Common Terminology Criteria (CTC) version 5.0.
Time frame: 2 years
Secondary
progression-free survival (PFS)
Time frame: 12 month
Eligibility criteria
Study locations (7)
Memorial Sloan Kettering Basking Ridge (Limited protocol activities)
Basking Ridge, New Jersey, 07920
Memorial Sloan Kettering Monmouth (Limited protocol activities)
Middletown, New Jersey, 07748
Memorial Sloan Kettering Bergen (Limited protocol activities)
Montvale, New Jersey, 07645
Memorial Sloan Kettering Suffolk - Commack (Limited protocol activities)
Commack, New York, 11725
Memorial Sloan Kettering Westchester (Limited protocol activities)
Harrison, New York, 10604
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
Memorial Sloan Kettering Nassau (Limited protocol activities)
Rockville Centre, New York, 11553